.png){kind=icon}
返回
Pacemaker-Mediated Programmable Hypertension Control Therapy
.png){kind=icon}
OA
AI
DOI：10.1161/JAHA.117.006974.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Background-Many patients requiring a pacemaker have persistent hypertension with systolic blood pressures above recommended levels. We evaluated a pacemaker-based Programmable Hypertension Control (PHC) therapy that uses a sequence of variably timed shorter and longer atrioventricular intervals. Methods and Results-Patients indicated for dual-chamber pacing with office systolic blood pressure (oSBP) > 150 mm Hg despite stable medical therapy were implanted with a Moderato (TM) pulse generator that delivers PHC therapy. Patients were followed for 1 month (Run-In period) with conventional pacing; those with persistent oSBP > 140 mm Hg were included in the study and had PHC therapy activated. The co-primary efficacy end points were changes in 24-hour ambulatory systolic blood pressure and oSBP between baseline and 3 months. Safety was assessed by tracking adverse events. Thirty-five patients met the initial inclusion criteria and underwent Moderato implantation. At 1 month, oSBP was < 140 mm Hg in 7 patients who were excluded. PHC was activated in the remaining 27 patients with baseline office blood pressure 166 +/- 11/80 +/- 10 mm Hg despite an average of 3.2 antihypertensive medications. During the Run-In period, oSBP and 24-hour ambulatory systolic blood pressure decreased by 8 +/- 13 and 5 +/- 12 mm Hg (P<0.002), respectively. Compared with pre-PHC activation measurements, oSBP decreased by another 16 +/- 15 mm Hg and 24-hour ambulatory systolic blood pressure decreased by an additional 10 +/- 13 mm Hg (both P<0.01) at 3 months. No device-related serious adverse effects were noted. Conclusions-In pacemaker patients with persistent hypertension despite medical therapy, oSBP and 24-hour ambulatory systolic blood pressure are decreased by PHC therapy. Initial indications are that this therapy is a safe and promising therapy for such patients.
Keyword:
Hypertension
Pacing
AV Delay
Isolated Systolic Hypertension
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
5.3
论文数:
1.1W
被引数:
4.5W
机构
查看更多机构
引用论文
Oxysulfide Semiconductors for Photocatalytic Overall Water Splitting with Visible Light用于可见光光催化整体水分解的硫氧化物半导体
PREAI
分享收藏Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy Results of the 6-Year Open Follow-Up.png)
HYPERTENSIONOAAI
HYPERTENSIONIF8.2
OAAI分享收藏分享收藏Determination of the optimal atrioventricular delay in DDD pacing - Comparison between echo and peak endocardial acceleration measurementsEUROPACE
EUROPACEIF7.4
PREAI
分享收藏Evaluation of left atrial contraction contribution to left ventricular filling using cardiovascular magnetic resonance心血管磁共振评价左心房收缩对左心室充盈的贡献OAAI
OAAI分享收藏 查看更多内容